SNWV
SANUWAVE Health, Inc.31.46
-0.18-0.57%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
269.81MP/E (TTM)
-Basic EPS (TTM)
-0.73Dividend Yield
0%Recent Filings
8-K
Record Q4, FY revenues
Sanuwave Health smashed records with Q4 2025 revenue at $13.4 million, up 29.7% year-over-year, and full-year $44.1 million, up 35.0%. UltraMIST systems and consumables drove nearly all growth amid CMS reimbursement cuts shaking wound care. Guidance calls for Q1 2026 revenue of $9.6-10.3 million and full-year $51.0-55.0 million. Gross margins dipped to 74.7% from a $0.5 million PACE inventory write-off.
10-K
FY2025 results
Sanuwave crushed FY2025 with $44.1M revenue, up 35% y/y from $32.6M, fueled by 24% consumables growth and 67% UltraMIST system sales surge; Q4 momentum accelerated via reseller channels despite slight ASP dip. Gross margins expanded to 77% from 75% on pricing and cost tweaks, driving operating income to $4.9M, up 29%. Debt refinanced into $23M term loan plus $5M revolver, bolstering liquidity after $11.8M net income. Cash from ops hit $3.9M. Material weaknesses persist in controls.
8-K
Restates financials for tax liabilities
Sanuwave Health disclosed on March 13, 2026, that prior financials for 2024 quarters and year can't be relied upon due to unrecorded state sales tax liabilities from nexus issues. Audit committee, with input from management and auditors Baker Tilly and Marcum, flagged restatements. Expects $4.9M-$5.2M added liabilities at Dec 31, 2025, plus $1.6M-$1.8M expenses for 2024 and $1.7M-$1.9M for 2025, including penalties. Internal controls under review.
8-K
Record Q3 revenues, Q4 guidance
Sanuwave posted record Q3 revenues of $11.5 million, up 22% from $9.4 million last year, driven by 155 UltraMist systems sold and 26% consumables growth to $6.8 million. Gross margin hit 77.9%, but GAAP operating income dipped to $1.5 million from $2.0 million due to $1.4 million stock-based compensation. Q4 guidance: $13-$14 million. Reimbursement clarity boosts pipeline.
10-Q
Q3 FY2025 results
SANUWAVE Health posted Q3 revenue of $11.5M, up 22% y/y from $9.4M, with gross margin expanding to 78% from 76% on UltraMIST® volume growth. Operating income dipped 25% y/y to $1.5M amid $1.4M stock-based comp, yet YTD operating income rose 50% to $4.3M on 39% revenue growth. Debt refinanced September 25 with $23M term loan (maturing 2029) and $5M revolver ($4.3M available); cash ended at $9.6M, OCF YTD $0.6M. Diluted EPS fell to $0.46 from anti-dilution effects. Swung to $10.3M net income on $6.1M warrant fair-value gain and $5M patent sale. Warrants remain volatile.
EMED
Electromedical Technologies, In
0.00+0.00
ENDV
Endonovo Therapeutics, Inc.
0.00+0.00
ENOV
Enovis Corporation
26.07-0.47
NAOV
NanoVibronix, Inc.
4.02-0.29
NUMD
Nu-Med Plus Inc.
0.02-0.01
NUWE
Nuwellis, Inc.
2.21+0.03
NVNO
enVVeno Medical Corporation
0.32+0.01
PROF
Profound Medical Corp.
7.55-0.14
SNN
Smith & Nephew SNATS, Inc.
32.31+0.08
SONX
Sonendo, Inc.
0.20-0.07